Gentronix signs genotoxicity assays agreement with GSK
Gentronix to provide GreenScreen HC and BlueScreen HC genotoxicity assays to GlaxoSmithKline (GSK).
Gentronix is to provide GreenScreen HC and BlueScreen HC genotoxicity assays to GlaxoSmithKline (GSK) for the next three years.
This agreement extends an existing relationship between the two companies in respect of GreenScreen HC, to include GSK's use of BlueScreen HC in 384 well format. BlueScreen HC is the latest Gentronix human cell reporter-based assay for compound profiling.
Gentronix, based in Manchester, UK, says GreenScreen HC was the first human cell-based assay technology to combine high sensitivity for detecting genotoxic chemicals with high specificity for reducing false positive results. It gives rapid results, provides additional data for safety profiling and consumes low quantities of compound.
BlueScreen HC is a Luciferase-based assay that combines all of the features of GreenScreen HC with the ability to be run in 384 well format. It is said to provide a viable route to early detection of genotoxicity.
The assays are able to detect known classes of genotoxic agent, and use Green Fluorescent Protein or Gaussia Luciferase to detect GADD-45a up-regulation, which is a key indicator of DNA damage.